

Individual Patient Funding Request

Deep Dive

Progress Presentation

Deep dive authors: Oliver Harness, Senior IPFR Manager & Rachel Gemine, Assistant Director of Evidence, Evaluation and Effectiveness
SRO - Iolo Doull, Medical Director

Executive Summary

Key Messages:

- **IPFR Deep dive** to review 24-25 & 25-26 financial years of Prior Approval and true IPFR applications, totalling **3906**.
- **Data quality issues** resulted in circa **1000** records needing validation
- **Predicted deep dive recommendation themes**
 - Additional resources required to facilitate acquisition of PROMs, PREMs, and life-long treatment monitoring
 - Mechanisms required to trigger repatriation of high demand services
 - Defining JCC and UHB commissioning responsibilities

Overview

- 3908 recorded funding requests, plus additional 13 weekly non-recorded queries
- 3361 requests (86%) were approved, 28% provided within Wales
- 117 different public and private health care providers cared for patients in Wales, England, Scotland, Ireland and Europe.
- Nine key providers provided 52% of all care, Cardiff and Vale UHB providing 492 episodes of care

Finance, Value and Effectiveness

- Total approved maximum value £59.3m IPFR & Prior Approval, of which £4m IPFR
- Currently no mechanisms in place to record PROM's and PREM's
- Deep dive of 24-25 activity shows 75% of approved maximum value later invoiced by providers*
- 73 approvals approved prior to 24-25 have financial commitments in 26-27. **


Recommendation:

- Processes and resources be established in patient care team to support PROM, PREM attainment and life-long treatment monitoring


* Activity excludes approved applications invoiced through SLA, and that paid to date

** Evaluation on-going to establish reasons for difference between approved value and that invoiced

IPFR Geographical Distribution



Approved requests per UHB



Treatment centres (NHS E. Grouped to ICB)


IPFR review

- 304 IPFR applications received, of which 80% were approved**
 - 61 IPFR applications declined, nearly half (48%) for Plastic Surgery*
 - 41 (76%) cases declined as panel not satisfied the clinical presentation of the patient's condition was significantly different to comparator group.
-


* Evaluation on-going to establish reasons for high Plastic Surgery representation in declined cohort

** Benchmarking of declined rate against NHS Wales and wider health organisations

Prior Approval Geographical Distribution



Approved Maximum Value per head population (£)



Treatment centres (NHS E. Grouped to ICB)

Repeated IPFR Requests

During deep dive period application approved included:

- **Six requests** for Blinatumomab to treat Acute Lymphoblastic Leukaemia
- **Three requests** for Anakinra cases to treat Autoinflammatory syndrome
- **Four requests** for Emicizumab to treat moderate Haemophilia A

IPFR Treatment Approved	#	Sum AMV
PET Scan	100	£107,200
Prosthesis / Equipment	24	£368,874
LAAO	8	£108,000
Blinatumomab	6	£473,274
PRRT	6	£244,574
Anakinra	6	£50,668
Emicizumab	5	£222,247
Dupilumab	4	£97,637
Ruxolitinib	4	£84,068
Tocilizumab	4	£66,061
IVF	4	£24,594
Percutaneous Transcatheter Tricuspid Valve	3	£94,037
Mitral & Pulmonary Valve Replacement	3	£75,000
Baricitinib	3	£26,292
Etanercept	3	£17,931

Recommendation:

- Process to **adopt recurrent IPFRs** into routine commissioning

High Frequency Prior Approval Requests - Organisations

- 28% of patients received care within Wales (excluding DAFH*)
- 17% of patients received care within the boundaries of their resident UHB (excluding DAFH*)


Top 14 Treating Organisation	No. Approved Applications	Sum AMV
Calea COMM (HPN)	160	£15,818,673
CARDIFF & VALE UNIVERSITY LHB	375	£8,690,979
THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST	34	£5,013,411
HAMPSHIRE HOSPITALS NHS FOUNDATION TRUST	27	£1,935,687
MANCHESTER UNIVERSITY NHS FOUNDATION TRUST	38	£1,876,421
GUY'S AND ST THOMAS' NHS TRUST	148	£1,792,091
Oxford University Hospitals NHS Foundation Trust	192	£1,748,962
Lloyds Pharmacy Clinical Homecare Ltd (HPN)	22	£1,610,755
University Hospitals Bristol NHS Foundation Trust	110	£1,312,898
Sheffield Teaching Hospitals NHS Foundation Trust	195	£1,250,775
ROYAL FREE LONDON NHS FOUNDATION TRUST	56	£1,080,766
THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST	53	£948,513
SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST	26	£845,588
ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST	110	£735,631

Recommendation:

- Establish thresholds and mechanisms for repatriation of services into Wales

High Demand Services – Home Parenteral Nutrition

LHB of Residence	Count	Sum AMV (£)	AMV per head population	Median AMV
Cardiff & Vale UHB	36	£3,421,559	£6.58	£90,843
Aneurin Bevan UHB	49	£4,536,189	£7.54	£86,346
Cwm Taf Morgannwg UHB	33	£3,624,073	£8.07	£103,773
Betsi Cadwaladr UHB	40	£4,441,193	£11.41	£110,255
Hywel Dda UHB	18	£1,386,599	£1.99	£70,186
Powys Teaching HB	9	£735,158	£5.44	£98,082
Swansea Bay UHB	14	£997,849	£2.53	£65,805



Recommendation:

- Review of HPN **prescribing practices** to ensure equity across Wales

Predicted Recommendations

1. **Redesign Prior Approval pathway to** include inhouse Power Apps development or Prior Approval system providers such as Blueteq with functional Power BI dashboard.
 2. Establish **thresholds** and **mechanisms** for repatriation of services into Wales
 3. **Improve PROM & PREM** collection to evidence effectiveness and value of care provided
 4. **Review funding mechanisms** for patients receiving life long high-cost drugs, with annual clinical validation
 5. Process to **adopt recurrent IPFRs** into routine commissioning
 6. Defining **JCC and UHB** commissioning responsibilities
- Further recommendations deferred until supporting evidence confirmed



GIG
CYMRU
NHS
WALES

Cyd-bwyllgor
Comisiynu
Joint Commissioning
Committee

Diolch/Thank you
